Expression of IL-33 by tumor cells promotes CD8 T cell-mediated anti-tumor responses in various cancer models, including colorectal cancer [9], pancreatic ductal adenocarcinoma (PDAC) [10], melanoma and breast cancer [6] and is required for immune checkpoint blockade (ICB) efficacy [9, 11]. This evidence concerns the gene IL33 and neoplasm.